Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients with Severe Liver Cirrhosis (Child

Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients with Severe Liver Cirrhosis (Child–Pugh Class C)

Published:2018-07-01 Issue:7 Volume:41 Page:1112-1118
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Yamada Takehiro¹,Imai Shungo¹,Koshizuka Yasuyuki²,Tazawa Yuki¹,Kagami Keisuke¹,Tomiyama Naoki¹,Sugawara Ryosuke¹,Yamagami Akira¹,Shimamura Tsuyoshi³,Iseki Ken¹⁴

Affiliation:

1. Department of Pharmacy, Hokkaido University Hospital

2. Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine

3. Division of Organ Transplantation, Hokkaido University Hospital

4. Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Laboratory of Clinical Pharmaceutics and Therapeutics

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/41/7/41_b18-00164/_pdf

Reference31 articles.

1. 1) Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol., 36, 198–202 (1998).

2. 2) Karthaus M. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin-review of the literture. Eur. J. Med. Res., 16, 145–152 (2011).

3. 3) Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol., 42, 395–402 (2002).

4. 4) Saravolatz LD, Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis., 36, 630–637 (2003).

5. 5) Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukamizu T, Shimodozono Y, Morikawa N, Takeda Y, Yamada K. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int. J. Antimicrob. Agents, 34, 91–94 (2009).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals;Frontiers in Genetics;2023-08-24

2. Optimization of Voriconazole Dosing Regimens Against Aspergillus Species and Candida Species in Pediatric Patients After Hematopoietic Cell Transplantation: A Theoretical Study Based on Pharmacokinetic/Pharmacodynamic Analysis;The Journal of Clinical Pharmacology;2023-05-11

3. Factors Influencing Blood Concentration of Voriconazole and Therapeutic Drug Monitoring in Patients with Child–Pugh Class C Cirrhosis;Journal of Clinical Pharmacy and Therapeutics;2023-02-14

4. Usefulness of the Albumin–Bilirubin Score in Determining the Initial Dose of Voriconazole for Patients with Liver Cirrhosis;Biological and Pharmaceutical Bulletin;2023-02-01

5. Is Halving Maintenance of Voriconazole Safe and Efficient in Patients Suffering from Invasive Fungal Infections with Serious Hepatic Dysfunction?;Infection and Drug Resistance;2023-01